COMy 2020 | Evidence supporting lenalidomide for high-risk smoldering myeloma patients
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the controversies in myeloma research. Two large Phase III trials have shown that early intervention with lenalidomide is highly beneficial for high-risk patients. A Spanish 10 year follow up study also indicated that early intervention improved survival. Therefore, high-risk patients should be enrolled in clinical trials and, if trial trials cannot continue, it would be reasonable to give patients short courses of lenalidomide. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Advisory board: Celgene, Takeda, Janssen, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Abbvie, Kayropharm
Research support: Celgene, BMS, Janssen, Takeda
Member of the board of directors TG therapeutics
